-
-
- Cat. No.
- A19517
JFD00244
JFD00244 is a sirtuin 2 (SIRT2) inhibitor. Anti-tumor effect.
In stock View Details -
- Cat. No.
- A19841
SIRT5 inhibitor 1
SIRT5 inhibitor 1 is a potent Human Sirtuin 5 deacylase inhibitor, with an IC50 of 0.11 μM.
In stock View Details -
- Cat. No.
- A20005
PROTAC Sirt2 Degrader-1
PROTAC Sirt2 Degrader-1 is a SirReal-based PROTAC, acts as a Sirt2 degrader, composed of a highly potent and isotype-selective Sirt2 inhibitor, a linker, and a bona fide cereblon ligand for E3 ubiquitin ligase.
In stock View Details -
- Cat. No.
- A20091
SirReal1-O-propargyl
Synonyms: PROTAC Sirt2-binding moiety 1
SirReal1-O-propargyl is a selective and highly potent Sirtuin 2 (Sirt2) inhibitor, with an IC50 of 2.4 μM.
In stock View Details -
- Cat. No.
- A20961
SIRT-IN-2
SIRT-IN-2 is a potent inhibitor of SIRT1/2/3, with IC50s of 4, 4, 7 μM, respectively.
In stock View Details -
- Cat. No.
- A20962
SIRT-IN-1
SIRT-IN-1 is a potent inhibitor of SIRT1/2/3, with IC50s of 15, 10, 33 μM, respectively.
In stock View Details -
- Cat. No.
- A21143
SRT 1720 Hydrochloride
Synonyms: SRT1720
SRT 1720 Hydrochloride is a selective activator of SIRT1 with an EC50 of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3.
In stock View Details -
- Cat. No.
- A22438
Gardenia yellow
Synonyms: Crocin I
Gardenia yellow is an active member of crocin, increases mRNA expression of SIRT3, and acts as an orally active antidepressant agent.
In stock View Details -
- Cat. No.
- A22709
4'-bromo-Resveratrol
4'-bromo-Resveratrol is a potent inhibitor of the deacetylases sirtuin 1 (SIRT1) and 3 (SIRT3).
In stock View Details -
- Cat. No.
- A24874
SIRT2-IN-8
Synonyms: Linazolamide intermediate B impurity 2; CPNQ; 5-[4-(4-Chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline
SIRT2-IN-8 is a selective inhibitor of SIRT2 (Sirtuin 2), a member of the sirtuin family of proteins implicated in various cellular processes. This compound exhibits strong inhibition of SIRT2 activity, making it a valuable tool for investigating the role of SIRT2 in neurodegenerative diseases, particularly Huntington's and Parkinson's diseases. Its use in research can contribute to a better understanding of the molecular mechanisms underlying these conditions and aid in the development of therapeutic strategies.
In stock View Details -
- Cat. No.
- A25886
SIRT6-IN-3
SIRT6-IN-3 is a selective inhibitor of SIRT6, exhibiting an IC50 of 7.49 μM. This compound effectively inhibits the proliferation of pancreatic ductal adenocarcinoma (PDAC) cells and promotes apoptosis. Additionally, SIRT6-IN-3 enhances the sensitivity of cancer cells to gemcitabine by obstructing the DNA damage repair pathway, making it a valuable tool in pancreatic cancer research.
In stock View Details -
- Cat. No.
- A26401
Mz325
Mz325 is a dual inhibitor of histone deacetylases (HDAC) and Sirtuin 2 (Sirt2), with an IC50 of 9.7 μM for Sirt2. By modulating deacetylation processes, Mz325 exhibits bioactivity that can influence cellular pathways involved in cancer progression and neurodegenerative diseases. This compound is useful for research focused on the role of epigenetic regulation in these pathologies.
In stock View Details -
- Cat. No.
- A26728
BML-278
BML-278 is a potent SIRT1 activator with an effective concentration (EC150) of 1 μM. It enhances histone modifications by increasing H3K9 methylation and inhibiting H3K9 acetylation, which contributes to improved early embryonic development. Additionally, BML-278 induces G1/S phase cell cycle arrest and reduces senescence in primary human mesenchymal cells. In U937 cells, this compound reduces tubulin acetylation while promoting increased mitochondrial density in murine C2C12 myoblasts, highlighting its versatility in cellular and developmental research applications.
In stock View Details -
- Cat. No.
- A29151
SL010110
SL010110 is an anti-hyperglycemic agent that specifically targets SIRT2 to inhibit gluconeogenesis. By activating p300, SL010110 promotes the degradation of PEPCK1, resulting in a significant downregulation of its protein levels without altering the gene expression of key gluconeogenic enzymes such as PEPCK, glucose-6-phosphatase, and fructose-1,6-bisphosphatase. This compound has demonstrated efficacy in improving glucose homeostasis in models of type 2 diabetes, making it a valuable tool for research into T2D mechanisms and therapeutic strategies.
Out of stock
All 3 sizes -
- Cat. No.
- A30090
SIRT7 inhibitor 97491
SIRT7 Inhibitor 97491 is a selective inhibitor of the SIRT7 enzyme, exhibiting an IC50 of 325 nM and effectively reducing its deacetylase activity in a dose-dependent manner. This compound enhances tumor suppression by stabilizing the p53 protein through acetylation at lysine residues K373 and K382. Additionally, SIRT7 Inhibitor 97491 promotes apoptosis via the caspase signaling pathway, making it a valuable tool for cancer research and studies focused on elucidating the role of SIRT7 in tumor progression.
In stock View Details -
- Cat. No.
- A30339
SIRT6 activator 12q
SIRT6 activator 12q is a potent and selective small molecule that acts as an activator of SIRT6, exhibiting an IC50 of 0.58 μM, while demonstrating much lower activity against other sirtuins such as SIRT1-3 and SIRT5. This compound has been shown to inhibit cell growth and migration, induce apoptosis, and cause cell cycle arrest at the G2 phase. With its potential anticancer properties, SIRT6 activator 12q is a valuable tool for research in cancer biology and therapeutic development targeting SIRT6 pathways.
In stock View Details -
- Cat. No.
- A30905
Myricanol
Myricanol is a diarylheptanoid that acts as a Nampt activator, enhancing SIRT1 and PRDX5 activities. This compound exhibits notable anti-inflammatory properties and mitigates glucocorticoid-induced muscle atrophy while regulating inflammatory mediators. Additionally, it demonstrates growth inhibition and promotes apoptosis in human lung adenocarcinoma A549 cells. Myricanol is also implicated in neuroprotection via autophagy-mediated clearance of microtubule-associated protein tau and contributes to cardiovascular health by inhibiting key signaling pathways such as PDGFRβ and NF-κB. Its activation of mitochondrial transcription factor A (TFAM) further supports anti-renal fibrosis effects and improves insulin sensitivity through AMPK activation.
In stock View Details -
- Cat. No.
- A30993
SZU-B6
SZU-B6 is a SIRT6-protein-targeting chimeric degrader that achieves a DC50 of 45 nM and 154 nM in SK-HEP-1 and Huh-7 cell lines, respectively. It effectively inhibits the proliferation of SK-HEP-1 cells with an IC50 of 1.51 μM and suppresses colony formation in both SK-HEP-1 and Huh-7 cells. Additionally, SZU-B6 induces apoptosis and causes a cell cycle arrest in the G2/M phase in SK-HEP-1 cells, demonstrating notable antitumor efficacy in mouse models. This compound serves as a valuable tool for studying the functional roles of SIRT6 in cancer research.
In stock View Details -
- Cat. No.
- A31054
JGB1741
Synonyms: ILS-JGB-1741
JGB1741 is a potent and selective inhibitor of SIRT1, exhibiting an IC50 of approximately 15 μM. It displays weak inhibitory effects on SIRT2 and SIRT3, with IC50 values greater than 100 μM. JGB1741 enhances the levels of acetylated p53, promoting p53-mediated apoptosis through modulation of the Bax/Bcl2 ratio, cytochrome c release, and PARP cleavage. This compound is valuable for research applications focusing on breast cancer.
In stock View Details -
- Cat. No.
- A31255
Sirt1/2-IN-2
Sirt1/2-IN-2 is a dual inhibitor targeting SIRT1 and SIRT2, exhibiting IC50 values of 1.8 μM and 2.4 μM, respectively. This compound effectively prevents the deacetylation of p53 while promoting acetylation of p53 and α-tubulin. Sirt1/2-IN-2 demonstrates pro-apoptotic properties and exhibits anti-proliferative effects on human leukemia cell lines, making it a valuable tool in cancer research and therapeutic studies targeting the sirtuin family.
In stock View Details -
- Cat. No.
- A31657
Sirt1/2-IN-3
Sirt1/2-IN-3 is a dual inhibitor of the sirtuin family, specifically targeting SIRT1 and SIRT2 with IC50 values of 1.4 μM and 2.0 μM, respectively. This compound effectively prevents the deacetylation of p53, leading to increased acetylation of both p53 and α-tubulin. Sirt1/2-IN-3 has been demonstrated to induce apoptosis and exhibit anti-proliferative effects on human leukemia cell lines, making it a valuable tool for cancer research and the study of cellular aging mechanisms.
Out of stock
All 3 sizes -
- Cat. No.
- A31665
SIRT-IN-7
SIRT-IN-7 is a selective inhibitor targeting the SIRT family of proteins, specifically SIRT1, SIRT2, and SIRT3. This compound enhances the acetylation and activation of the tumor suppressor protein p53, leading to the inhibition of proliferation and the induction of apoptosis and autophagy in breast cancer cells. SIRT-IN-7 demonstrates significant anti-tumor activity, making it a valuable tool for research in cancer biology and therapeutic development.
Out of stock
All 3 sizes -
- Cat. No.
- A32313
Sirt1/2-IN-4
Sirt1/2-IN-4 is a potent triple inhibitor of the sirtuin family, specifically targeting SIRT1 and SIRT2 with IC50 values of 1.2 μM and 1.9 μM, respectively, and showing moderate inhibition of SIRT3 at 18.6 μM. This compound effectively prevents the deacetylation of p53, highlighting its potential role in cancer research. Its ability to modulate sirtuin activity makes it a valuable tool for investigating the biological implications of sirtuin inhibition in various cancer models.
Out of stock
All 3 sizes -
- Cat. No.
- A32741
SIRT6-IN-4
SIRT6-IN-4 is a selective inhibitor of SIRT6, demonstrating an IC50 of 5.68 μM. This compound effectively inhibits the proliferation of MCF-7 cells with an IC50 of 8.30 μM, leading to cell cycle arrest at the G2/M phase. Additionally, SIRT6-IN-4 reduces cell migration and invasion while inducing apoptosis. Its antitumor efficacy has been confirmed in mouse models, making it a valuable tool for cancer research and therapeutic development.
Out of stock
All 3 sizes